Biogen Inc. BIIB
NASDAQ · Healthcare · Drug Manufacturers - General
$249.59
Close on Fri, 20 Nov 2026 · market value $36.9B
What the price is betting on
Below its recordAt $250, the price assumes revenue shrinks about 5% a year for five years, from $10.3B to about $8.3B by FY2030. That is less than what analysts expect for the next two years and less than the company's own last three years.
Revenue growth a year. The price figure comes from a reverse DCF at a 6.2% discount rate.
Track it and Parra checks each report against the path, and tells you when revenue falls behind it.
Own more than BIIB? Check up to 5 of your stocks at once, free, no account.
Both sides
Three stories, three values
Bear
$366
Base
$413
Bull
$465
Today $250
- Bear $366. Cash flow grows 1% a year for the next 5 years, slower than expected, then slows to long-run growth.
- Base $413. Cash flow grows 3% a year for the next 5 years, as analysts expect, then slows to long-run growth.
- Bull $465. Cash flow grows 5% a year for the next 5 years, faster than expected, then slows to long-run growth.
Stories set by rules from the company’s record.
Checkpoints
The revenue the price needs
- YearNeedsAnalysts expect
- FY2026$10.2B$10.6B, on the path
- FY2027$9.7B$10.8B, on the path
- FY2028$9.2B$11.1B, on the path
- FY2029$8.7B$11.4B, on the path
- FY2030$8.3B$11.6B, on the path
Each year's revenue at −5% growth from $10.3B in the 12 months to September 2026.
At a glance
Healthcare · Drug Manufacturers - General · listed on NASDAQ
- Revenue, FY2025
- $9.9B
- Growth, 3 years a year
- 1.7%
- Cash margin
- 21%
- Net debt
- $3.1B
- Shares, 3-year change
- +0.8%
- Dividend yield
- 0%
What other healthcare prices are betting on
Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.